Logo image of INO

INOVIO PHARMACEUTICALS INC (INO) Stock Fundamental Analysis

NASDAQ:INO - Nasdaq - US45773H4092 - Common Stock - Currency: USD

1.87  +0.02 (+1.08%)

After market: 1.8701 +0 (+0.01%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to INO. INO was compared to 568 industry peers in the Biotechnology industry. The financial health of INO is average, but there are quite some concerns on its profitability. INO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INO has reported negative net income.
In the past year INO has reported a negative cash flow from operations.
In the past 5 years INO always reported negative net income.
In the past 5 years INO always reported negative operating cash flow.
INO Yearly Net Income VS EBIT VS OCF VS FCFINO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

INO's Return On Assets of -94.75% is on the low side compared to the rest of the industry. INO is outperformed by 74.65% of its industry peers.
The Return On Equity of INO (-156.57%) is worse than 64.26% of its industry peers.
Industry RankSector Rank
ROA -94.75%
ROE -156.57%
ROIC N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
INO Yearly ROA, ROE, ROICINO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INO Yearly Profit, Operating, Gross MarginsINO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

5

2. Health

2.1 Basic Checks

INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
INO has more shares outstanding than it did 1 year ago.
INO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for INO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INO Yearly Shares OutstandingINO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
INO Yearly Total Debt VS Total AssetsINO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -23.10, we must say that INO is in the distress zone and has some risk of bankruptcy.
INO has a Altman-Z score of -23.10. This is amonst the worse of the industry: INO underperforms 87.50% of its industry peers.
There is no outstanding debt for INO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.1
ROIC/WACCN/A
WACC10.24%
INO Yearly LT Debt VS Equity VS FCFINO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 2.77 indicates that INO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.77, INO is doing worse than 67.96% of the companies in the same industry.
INO has a Quick Ratio of 2.77. This indicates that INO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INO (2.77) is worse than 66.20% of its industry peers.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.77
INO Yearly Current Assets VS Current LiabilitesINO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.23% over the past year.
INO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -73.82%.
The Revenue for INO have been decreasing by -44.44% on average. This is quite bad
EPS 1Y (TTM)35.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
Revenue 1Y (TTM)-73.82%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%13.98%

3.2 Future

Based on estimates for the next years, INO will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.16% on average per year.
The Revenue is expected to grow by 361.81% on average over the next years. This is a very strong growth
EPS Next Y40.31%
EPS Next 2Y22.24%
EPS Next 3Y19.5%
EPS Next 5Y19.16%
Revenue Next Year2320.42%
Revenue Next 2Y1211.91%
Revenue Next 3Y702.37%
Revenue Next 5Y361.81%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INO Yearly Revenue VS EstimatesINO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
INO Yearly EPS VS EstimatesINO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INO Price Earnings VS Forward Price EarningsINO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INO Per share dataINO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

INO's earnings are expected to grow with 19.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.24%
EPS Next 3Y19.5%

More info and screens

0

5. Dividend

5.1 Amount

INO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (4/23/2025, 8:14:16 PM)

After market: 1.8701 +0 (+0.01%)

1.87

+0.02 (+1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2025-03-18/amc
Earnings (Next)05-12 2025-05-12
Inst Owners35.91%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change1.26%
Market Cap68.57M
Analysts78
Price Target7.99 (327.27%)
Short Float %15.64%
Short Ratio6.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.22%
Min EPS beat(2)23.41%
Max EPS beat(2)29.03%
EPS beat(4)2
Avg EPS beat(4)4.06%
Min EPS beat(4)-29.26%
Max EPS beat(4)29.03%
EPS beat(8)4
Avg EPS beat(8)3.64%
EPS beat(12)5
Avg EPS beat(12)0.43%
EPS beat(16)6
Avg EPS beat(16)-8.79%
Revenue beat(2)1
Avg Revenue beat(2)93.07%
Min Revenue beat(2)-100%
Max Revenue beat(2)286.14%
Revenue beat(4)1
Avg Revenue beat(4)17.06%
Min Revenue beat(4)-100%
Max Revenue beat(4)286.14%
Revenue beat(8)2
Avg Revenue beat(8)19.17%
Revenue beat(12)4
Avg Revenue beat(12)118.55%
Revenue beat(16)4
Avg Revenue beat(16)71.68%
PT rev (1m)-17.54%
PT rev (3m)-26.56%
EPS NQ rev (1m)-1.79%
EPS NQ rev (3m)30.38%
EPS NY rev (1m)19.19%
EPS NY rev (3m)26.08%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)16.92%
Revenue NY rev (3m)-2.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 314.84
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1
EV/EBITDA N/A
EPS(TTM)-3.99
EYN/A
EPS(NY)-2.38
Fwd EYN/A
FCF(TTM)-2.85
FCFYN/A
OCF(TTM)-2.84
OCFYN/A
SpS0.01
BVpS1.87
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -94.75%
ROE -156.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.58%
Cap/Sales 223.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.77
Altman-Z -23.1
F-Score2
WACC10.24%
ROIC/WACCN/A
Cap/Depr(3y)16.84%
Cap/Depr(5y)25.5%
Cap/Sales(3y)90.66%
Cap/Sales(5y)72.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
EPS Next Y40.31%
EPS Next 2Y22.24%
EPS Next 3Y19.5%
EPS Next 5Y19.16%
Revenue 1Y (TTM)-73.82%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%13.98%
Revenue Next Year2320.42%
Revenue Next 2Y1211.91%
Revenue Next 3Y702.37%
Revenue Next 5Y361.81%
EBIT growth 1Y14.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.31%
OCF growth 3YN/A
OCF growth 5YN/A